Learn what the endocannabinoid system (ECS) is, how it helps regulate balance throughout the body, and how cannabinoids like CBD and THC interact with this remarkable communication network.
Editor's Note (2026):
This article was originally published in July 2024 and has been substantially revised and expanded to reflect the evolving science, research, federal regulations, and marketplace surrounding CBD. We’ve also added updated information about CBD safety, the FDA regulatory landscape, changes to federal hemp law taking effect in November 2026, and how to better distinguish what we know, what we’re still learning, and where the evidence stands today.
CBD has become a familiar part of the wellness landscape, but understanding exactly what it is—and what we actually know about it—can still be confusing. Research continues to develop, new products continue to emerge, and the legal and regulatory landscape is still evolving.
This guide starts with the basics: what CBD is, how it differs from THC, what research tells us about its effects, and what to consider when deciding whether CBD has a place in your wellness routine.
CBD, short for cannabidiol, is a naturally occurring compound found in the cannabis plant. It is one of more than 100 compounds known as cannabinoids, which interact with biological systems in the body in different ways.
Unlike THC (tetrahydrocannabinol), CBD itself is not intoxicating and does not produce the characteristic “high” associated with THC. CBD can be derived from different varieties of cannabis, but many commercially available CBD products sold are made from hemp.1
Researchers are still learning how CBD works in the body, including its interactions with the endocannabinoid system (ECS) and other signaling systems.2 What CBD may do, what people use it for, and what scientific evidence currently supports are three different questions—and we'll explore each throughout this guide. Understanding those distinctions can help you make more informed decisions about CBD.
The short answer: it depends on the CBD product, where it comes from, how it is marketed, and where you live.
At the federal level, the 2018 Farm Bill removed hemp from the Controlled Substances Act's definition of marijuana. Under the law currently in effect, hemp generally includes cannabis and its derivatives containing no more than 0.3% delta-9 THC by dry weight. That change made it possible to legally cultivate and produce hemp—and derive CBD from it—under federal hemp regulations. 3
But qualifying as hemp does not automatically make every CBD product federally legal. The 2018 Farm Bill preserved the U.S. Food and Drug Administration's authority to regulate products containing cannabis and cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act. How a CBD product is formulated, labeled, marketed, and sold can therefore affect its legal status. 4
For example, the FDA currently maintains that CBD cannot lawfully be marketed as a dietary supplement or added to conventional food introduced into interstate commerce. Other types of CBD products are also subject to applicable federal requirements, and state and local laws may impose additional restrictions. 4
A Federal Hemp Law Change Is Coming in November 2026
The federal definition of hemp is changing again. Legislation enacted in November 2025 amended the definition, with the new provisions scheduled to take effect November 12, 2026. Among the changes, the new federal standard considers total THC, including THCA, rather than only delta-9 THC when determining whether cannabis qualifies as hemp. The law also creates additional restrictions affecting certain hemp-derived cannabinoid products. 5
What does that mean for CBD? The full impact will depend on a product's composition and how the new requirements are implemented. It also means that some products that qualify as hemp under today's federal definition may not qualify after the new provisions take effect. State laws add another layer. States can regulate hemp and CBD differently, including what types of products may be sold, where they may be sold, and who may purchase them.4
Bottom line: Don't assume that a product labeled “hemp-derived” or “CBD” is automatically legal everywhere. Check the laws where you live—and when traveling, the laws at your destination—because federal, state, and local requirements can differ and continue to change.
CBD is biologically active and can influence several signaling systems in the body, including the endocannabinoid system (ECS), which plays a role in regulating a range of physiological processes. Our bodies naturally produce their own endocannabinoids; CBD is a phytocannabinoid produced by the cannabis plant that can interact with this system in more indirect and complex ways.2
Researchers are still working to understand exactly how CBD produces its effects and why those effects can vary from person to person. What someone experiences can depend on factors including the amount of CBD consumed, how it is taken, the product's formulation, other compounds in the product, and individual differences in how the body responds.
CBD has been studied for a wide range of potential therapeutic uses, but the strength of the evidence varies considerably. Some uses have been studied in human clinical trials, while others remain preliminary. And although one prescription CBD drug has been reviewed and approved by the FDA for specific seizure disorders, most CBD products sold directly to consumers have not been evaluated or approved by the FDA for safety or effectiveness in treating a particular condition.
That doesn't mean there is no evidence to consider. It means we need to distinguish between what has been established, what research suggests, and what we still don't know. We'll look more closely at those distinctions later in this guide.
CBD itself does not produce the characteristic “high” associated with THC. But that doesn't necessarily mean every product labeled CBD is completely free of intoxicating compounds.
Full-spectrum CBD products can contain small amounts of THC along with other cannabinoids and plant compounds. Whether that amount produces noticeable effects can depend on the product, the amount consumed, and individual sensitivity. Products may also contain different amounts of THC than their labels indicate, which is one reason independent laboratory testing matters.7
You may also hear the term entourage effect used to describe the theory that cannabinoids, terpenes, and other cannabis compounds may work differently together than they do in isolation. The science is still evolving, so the entourage effect shouldn't be interpreted as a guarantee that a particular CBD product will produce a particular experience.
If avoiding THC is important—for personal, workplace, drug-testing, or other reasons—don't rely on the word “CBD” alone. Check the product label and its Certificate of Analysis (COA) to understand what cannabinoids the product actually contains.
CBD's effects are more complex than simply attaching to one receptor or triggering one response. Researchers have found that CBD can influence the body's endocannabinoid system (ECS) as well as other receptors, enzymes, and signaling pathways involved in maintaining physiological balance.
Unlike THC, CBD has relatively little direct activity at the ECS's primary cannabinoid receptors, CB1 and CB2. Instead, researchers believe CBD influences the ECS and other signaling systems through several indirect mechanisms. Exactly how those interactions translate into particular effects—and why responses can differ among people—continues to be studied.2
Want to go deeper? Our beginner's guide to the endocannabinoid system explains CB1 and CB2 receptors, endocannabinoids, enzymes, and how cannabinoids such as CBD and THC interact with this system.
CBD is often described as well tolerated, but that doesn't mean it is risk-free. CBD can cause side effects, interact with medications, and raise additional safety considerations for some people.
Research on prescription CBD has identified potential side effects including drowsiness or changes in alertness, diarrhea and other gastrointestinal symptoms, decreased appetite, and fatigue. CBD can also interact with medications, and higher therapeutic doses studied in clinical settings have been associated with liver injury. How these findings translate to the many doses and formulations found in over-the-counter CBD products is still being studied. 6 8
There are also important gaps in what we know. Researchers are still investigating the effects of regular, long-term CBD use, cumulative exposure from multiple CBD products, and how different methods of consumption may affect safety. 8
The FDA advises against CBD use during pregnancy and breastfeeding because of potential risks and insufficient safety data. CBD use in children requires particular care and medical guidance. Prescription CBD has been studied in children and is FDA-approved for seizures associated with certain forms of epilepsy. CBD and other cannabis-based treatments have also been investigated in pediatric research and used in clinical practice beyond those approved indications, but the quality and strength of evidence vary by condition and product. Commercial CBD products present additional considerations because they do not undergo the same FDA review, manufacturing controls, and dosing standards as an approved prescription drug. 4 6
If you take prescription or over-the-counter medications, have an underlying health condition, or are considering CBD for a specific health concern, talk with your physician or pharmacist about whether CBD is appropriate for you.
Laboratory / Preclinical Research
Scientists explore how CBD interacts with cells, receptors, and biological systems.These studies help generate questions and possible mechanisms.
Observational & Clinical Experience
Patient reports, clinician observations, case reports, and real-world data reveal patterns and raise important questions worth studying further.
Controlled Human Trials
Researchers test specific questions in well-designed studies to determine safety, effectiveness. dosing, and potential benefits.
Regulatory
Review
Regulatory bodies review the totality of evidence to determine whether a product meets standards for safety, quality, and appropiate use.
CBD research has expanded, but it has not kept pace with consumer interest and the rapidly evolving cannabis landscape. As legal and regulatory barriers to cannabis research have begun to ease, scientists have more opportunities to investigate questions that consumers, patients, and clinicians have been asking for years.10
Our understanding of CBD also comes from multiple forms of evidence, each offering a different lens. Controlled clinical trials can help determine whether a specific intervention is safe and effective under defined conditions, while observational research and clinical experience can reveal patterns in real-world use. Patient reports can surface experiences and questions worth investigating, and laboratory and animal studies can help researchers explore biological mechanisms and identify promising directions for further study.
No single type of evidence tells the whole story. Understanding what each can—and cannot—tell us provides a more complete picture of what we currently know about CBD.
The clearest evidence for a therapeutic use of CBD comes from certain seizure disorders. Purified prescription cannabidiol has been studied in controlled clinical trials and is FDA-approved as Epidiolex® to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year of age and older. 6
That approval is important—but it doesn't mean the evidence is equally strong for other CBD products or health conditions. The formulation and doses used in clinical research can differ substantially from commercially available CBD products.
Researchers are investigating CBD for a much broader range of potential applications, including pain, anxiety, inflammation, sleep, substance use disorders, skin health, and neurological conditions.1 Depending on the subject, the evidence may range from human clinical trials to observational studies, laboratory research, or animal models.
For example, CBD has demonstrated anti-inflammatory and antioxidant activity in preclinical research, prompting interest in potential applications ranging from skin health to neuroinflammation.
Early dermatology research is exploring CBD's effects on inflammation, oxidative stress, sebum production, and other processes relevant to the skin, but larger, well-controlled human studies are still needed before specific benefits can be established. 11
CBD is also being studied in substance use disorders. Research led by neuroscientist Yasmin Hurd, PhD, at Mount Sinai has investigated whether CBD may reduce cue-induced craving and anxiety in people with heroin use disorder, building on earlier preclinical findings and demonstrating how promising laboratory research can progress into controlled human investigation. 12
CBD's potential neuroprotective properties are not a new area of scientific interest. Research into the antioxidant and neuroprotective properties of cannabinoids, including CBD, dates back decades. The U.S. Department of Health and Human Services was assigned a patent—filed in 1999 and granted in 2003—covering certain uses of cannabinoids as antioxidants and neuroprotectants. The patent specifically identified non-intoxicating cannabinoids such as cannabidiol and contemplated potential applications involving neurodegenerative diseases, including Alzheimer's and Parkinson's disease. The patent has since expired. 13
That history also illustrates an unusual tension in U.S. cannabis policy. During much of the same period that a federal health agency held a patent covering potential antioxidant and neuroprotective uses of cannabinoids, marijuana remained classified as a Schedule I controlled substance under federal law. That classification and other federal requirements created significant barriers to conducting cannabis research. 13 14
The research landscape began to change as federal policy changed. The 2018 Farm Bill removed qualifying hemp—and its derivatives, including hemp-derived CBD that met the federal THC threshold—from the Controlled Substances Act. Subsequent federal reforms have further sought to reduce barriers to cannabis and CBD research. These changes didn't establish CBD as a treatment for neurodegenerative disease, but they have expanded opportunities to investigate scientific questions that had been developing for decades. 3 10
Removing research barriers doesn't close evidence gaps overnight. Well-designed human studies take time, funding, regulatory approvals, standardized products, and enough participants to produce meaningful results. CBD research also has to contend with wide variations in formulations, doses, methods of administration, and the presence of other cannabinoids—all of which can make findings difficult to compare across studies. 14
Meanwhile, real-world experience has also played an important role in shaping research questions. Patient reports, clinician observations, case reports, and observational studies can reveal patterns and point researchers toward areas worth investigating. They can't establish cause and effect or demonstrate efficacy in the same way well-controlled clinical trials can, but they shouldn't be dismissed simply because they are not randomized controlled studies.
One challenge in interpreting CBD research is that studies don't always investigate the same thing. Researchers may use purified prescription CBD, isolated cannabidiol, CBD-dominant cannabis extracts, or products containing CBD alongside THC and other compounds. Doses and methods of administration can also differ substantially.
That's why findings involving cannabis or cannabinoids generally shouldn't automatically be attributed to CBD alone. Likewise, results from a study using a specific dose and formulation of purified CBD don't necessarily predict what someone will experience with a commercially available CBD product. 16
The science of CBD is neither simply “proven” nor “unproven.” What we know depends on the question being asked, the formulation studied, how it was used, and the quality and stage of the evidence. As research catches up, some long-standing observations may gain stronger scientific support, others may not—and new possibilities may emerge.
The FDA's relationship with CBD can seem contradictory. CBD products are widely available in stores and online, yet—with one important exception—the FDA has not approved commercially available CBD products as drugs or established a comprehensive regulatory pathway specifically designed for the broader CBD marketplace.
The exception is Epidiolex®, a purified prescription form of cannabidiol that went through the FDA drug-review process and is approved for seizures associated with certain rare disorders. That approval applies to the specific prescription drug, its formulation, dosing, and approved uses; it is not an FDA approval of CBD products generally. 6
The FDA also retains authority over CBD products that fall within areas it regulates, including drugs, foods, dietary supplements, cosmetics, and animal products. As discussed earlier, the agency maintains that CBD cannot currently be lawfully marketed as a dietary supplement or added to conventional food introduced into interstate commerce. 4
In 2023, after reviewing the available evidence, the FDA concluded that its existing regulatory pathways for conventional foods and dietary supplements were not appropriate for CBD. The agency cited safety concerns—including questions about long-term use, drug interactions, liver effects, and cumulative exposure—and said a new regulatory pathway was needed that could provide appropriate safeguards while preserving consumer access. The FDA called on Congress to create that framework. 17
More than three years later, that comprehensive federal pathway still has not been enacted. Congress has considered multiple proposals addressing CBD and hemp-derived cannabinoid products, including legislation involving manufacturing standards, labeling, serving limits, testing, and other consumer protections, but the fundamental regulatory gap remains. 17 18
The consequences are not merely bureaucratic. Consumers have continued buying CBD products while the regulatory system has remained unresolved. Without a comprehensive federal framework tailored to these products, standards for testing, labeling, cannabinoid content, manufacturing, and product quality can vary, and state requirements may fill some gaps differently from one jurisdiction to another.7 17
That leaves consumers in an unusual position: CBD is readily accessible, but the federal rules governing many of the products they encounter have not caught up with the marketplace.
Regulation and access don't have to be opposing goals. A clear framework could establish standards for product quality, testing, labeling, dosing, and consumer protections while giving researchers, healthcare professionals, responsible businesses, and consumers greater clarity about the products being studied, recommended, sold, and used.
Editor's Perspective: Through my work with the National Cannabis Industry Association, I've heard repeatedly from colleagues returning from federal Lobby Days about the significant education gap they encounter around hemp, CBD, cannabis, and the differences among them. That experience has reinforced for me how difficult it is to create effective policy when the science, marketplace, and terminology are evolving faster than the policy conversation.
There is another layer to the challenge. The FDA's concerns about gaps in CBD safety data developed during decades when federal restrictions also made cannabis and cannabinoid research more difficult. Those concerns shouldn't be dismissed—but neither should the historical barriers that contributed to an incomplete evidence base. As those barriers ease, a stronger body of research can help inform the kind of evidence-based regulatory framework that consumers and responsible businesses have been waiting for..14 17
With so many CBD products available—and no comprehensive federal regulatory framework governing the marketplace—knowing what to look for matters. You don't need to become a cannabinoid expert before choosing a product, but a few basic checks can help you make a more informed decision.
Ready to go deeper? Explore our guides for step-by-step help when choosing and evaluating CBD products: Types of CBD Products, Full-Spectrum vs. Broad-Spectrum vs. CBD Isolate, How to Read a CBD Label, and How to Read a Certificate of Analysis (COA).
There isn't one standard CBD amount that's right for everyone or every product. If you're new to CBD, a common approach is to start low and go slow: begin with a low serving, give yourself time to understand how you respond, and increase gradually if needed.19
Pay attention to the amount of CBD per serving, not simply the total milligrams listed on the package. If you're taking medications or using CBD for a particular health concern, talk with a knowledgeable physician or pharmacist before getting started.
How quickly you may notice CBD depends largely on how you use it. Inhaled CBD generally reaches the bloodstream more quickly, while swallowed products such as capsules and edibles typically take longer because they pass through the digestive system. Products used under the tongue may fall somewhere in between.16
Rather than expecting CBD to work on an exact timetable, consider the product type and give it enough time before deciding whether to take more. Our guide to Types of CBD Products explains how different delivery methods compare.
There isn't a single duration that applies to CBD. How long its effects may be noticeable depends on factors including the method of use, amount consumed, formulation, frequency of use, and individual metabolism.16
In general, products that take longer to produce effects may also last longer than faster-acting methods. Keep track of your own experience rather than assuming another person's timeline will be yours.
CBD itself generally isn't what standard workplace drug tests are looking for—but THC can be. Full-spectrum CBD products may contain THC, and repeated use can increase the possibility that THC metabolites will be detected.
Products labeled broad-spectrum or THC-free may reduce that risk, but labeling isn't always accurate and no commercial CBD product can guarantee that you'll pass a drug test. If drug testing matters to you, review a current Certificate of Analysis (COA) rather than relying solely on the front label.7 20
Many people use CBD regularly, but we don't yet have complete answers about the effects of long-term, everyday use, particularly across the wide range of doses and commercial formulations available.
Regular use also makes medication interactions, cumulative exposure, and the amount of CBD you're taking more important considerations. If CBD is part of your daily routine—especially if you take medications—discuss it with your physician or pharmacist.8
They aren't the same thing. CBD oil contains cannabidiol extracted from the flowers, leaves, and other cannabinoid-rich parts of hemp or cannabis. Hemp seed oil is pressed from hemp seeds and naturally contains little to no CBD.4
Hemp seed oil can be used as a food or cosmetic ingredient and may also appear as a carrier oil in a CBD product. When shopping, check the ingredient list and cannabinoid content rather than assuming anything labeled “hemp oil” contains CBD.
These terms describe what's included alongside the CBD. Full-spectrum products contain CBD along with other naturally occurring cannabis compounds and can contain THC. Broad-spectrum products contain CBD and other plant compounds but are generally processed to remove THC. CBD isolate is cannabidiol separated from the plant's other cannabinoids and compounds.
For a deeper comparison—including why someone might choose one over another—see our guide to Full-Spectrum vs. Broad-Spectrum vs. CBD Isolate.
CBD doesn't necessarily produce an obvious sensation, and because it isn't intoxicating, you shouldn't expect to feel “high” as evidence that it's working.
Instead, think about why you chose to try CBD and pay attention to whether anything meaningfully changes over time. Keeping a simple record of the product, amount, timing, and what you notice can make it easier to evaluate your experience rather than relying on a single impression.
Learn what the endocannabinoid system (ECS) is, how it helps regulate balance throughout the body, and how cannabinoids like CBD and THC interact with this remarkable communication network.
Learn the differences between CBD extracts, product types, and common terminology so you can better understand product labels, compare formulations, and make informed decisions with confidence.
Learn how to read a CBD label with confidence. Discover what labels reveal, how Certificates of Analysis (COAs) verify product quality, and what to look for before purchasing hemp-derived CBD products.
Learn how to read a Certificate of Analysis (COA), understand laboratory testing results, verify cannabinoid content, and make confident, informed choices about cannabis and hemp-derived products.
Learn what the endocannabinoid system (ECS) is, how it helps regulate balance throughout the body, and how cannabinoids like CBD and THC interact with this remarkable communication network.
Learn the differences between CBD extracts, product types, and common terminology so you can better understand product labels, compare formulations, and make informed decisions with confidence.
Learn how to read a CBD label with confidence. Discover what labels reveal, how Certificates of Analysis (COAs) verify product quality, and what to look for before purchasing hemp-derived CBD products.
Learn how to read a Certificate of Analysis (COA), understand laboratory testing results, verify cannabinoid content, and make confident, informed choices about cannabis and hemp-derived products.
Copyright © 2026 Green Bee Life | Green Bee LLC, is a subsidiary of Green Life Media, Inc., a full service creative agency and production company.
